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Left ventricular dysfunction is a rare side eﬀect of bevacizumab occurring in 2–4% of cases. We report the case of a 68-year-old
woman who presented to the emergency department (ED) with sudden onset of shortness of breath, orthopnea, and paroxysmal
nocturnal dyspnea. She was tachypneic and in respiratory distress. Physical examination revealed jugular venous distention,
diﬀuse expiratory wheeze, and bipedal edema. She had been started on bevacizumab for the treatment of hereditary
hemorrhagic telangiectasia 1 month prior to presentation. Laboratory tests revealed BNP of 1697 pg/ml with slightly elevated
troponin 0.05 ng/ml. Chest X-ray showed interstitial edema with cardiomegaly, and transthoracic echocardiogram showed
ejection fraction of 30% with global hypokinesia. Left heart catheterization revealed widely patent coronary arteries. Flash
pulmonary edema secondary to acute left ventricular dysfunction in this case was attributed to recent treatment with
bevacizumab after ruling out other possible etiologies. This case highlights the importance of early recognition of this rare but
potentially reversible side eﬀect of bevacizumab to prevent long-term sequelae.

1. Introduction

2. Case Report

Bevacizumab is a humanized monoclonal IgG antibody
against vascular endothelial growth factor (VEGF) [1]. VEGF
plays an important role in developmental angiogenesis [2].
Substantial evidence also implicates VEGF as a mediator of
pathologic angiogenesis—a hallmark feature of hereditary
hemorrhagic telangiectasia (HHT) [3]. Bevacizumab is
approved by the FDA as ﬁrst-line treatment for a wide range
of ophthalmologic diseases and malignancies, including glioblastoma, breast cancer, and metastatic colorectal cancer [4].
In addition, it is also used as oﬀ-label treatment of hereditary
hemorrhagic telangiectasia-related refractory bleeding [5].
The main cardiovascular side eﬀects of bevacizumab include
hypertension, bleeding, and venous and arterial thromboembolism [4]. In about 2–4% of cases, bevacizumab causes
reversible cardiomyopathy and left ventricular dysfunction
even in patients without preexisting cardiac disease [6].
Prompt recognition and early treatment with guidelinedirected medical therapy along with bevacizumab discontinuation are crucial in treating this potentially reversible but
fatal side eﬀect.

A 68-year-old woman with past medical history of hypertension, chronic kidney disease stage 3, hyperlipidemia, and
hereditary hemorrhagic telangiectasia (HHT) presented to
the emergency department with sudden onset of shortness
of breath. She also reported chest pain, orthopnea, and paroxysmal nocturnal dyspnea. Review of systems was otherwise
unremarkable. Her HHT was previously managed by regular
blood transfusions and epsilon-aminocaproic acid. Because
of the need for frequent blood transfusion due to persistent
epistaxis and gastrointestinal bleeding, she was started on
bevacizumab infusion at 15 mg/kg/dose (1150 mg total) by
her haematologist a month prior to presentation. Initial vital
signs on presentation revealed respiratory rate of 25/min,
oxygen saturation of 65% on ambient air, blood pressure of
138/83 mmHg, and pulse rate of 92/min. Physical examination revealed respiratory distress with diﬀuse wheeze, jugular
venous distention, and trace pedal edema. Laboratory tests
revealed markedly elevated brain natriuretic peptide (BNP)
of 1697 pg/ml (normal 0–100 pg/ml) with initial troponin of
0.05 ng/ml (normal < 0.04 ng/ml). Chest X-ray revealed
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pulmonary vascular congestion and interstitial edema with
mild cardiomegaly. She was immediately placed on noninvasive ventilation and started on intravenous furosemide with
quick symptomatic improvement. Transthoracic echocardiogram (TTE) showed ejection fraction of 30% and global
hypokinesia (please see Supplementary Materials (available
here)). Of note, TTE done three years prior to index presentation showed ejection fraction of 56%. She does not drink
alcohol, and her thyroid function and sedimentation rate
were normal making other etiologies of acute systolic heart
failure such as thyroid disorder, alcoholic, or inﬂammatory
cardiomyopathy less likely.
She refused to wear LifeVest and was placed on
guideline-directed medical therapy including beta-blocker,
angiotensin-converting enzyme inhibitor (ACEi), and aldosterone antagonist along with an oral diuretic. The patient
progressively improved and was discharged three days later
and scheduled for follow-up with cardiology for outpatient
right and left heart catheterization. Two weeks later, she
developed another episode of ﬂash pulmonary edema
deemed to be due to medication noncompliance. On this
occasion, she underwent left and right heart catheterization
which revealed widely patent coronary vessels (Figure 1),
elevated pulmonary capillary wedge pressure, and elevated
left ventricular end-diastolic pressure. She continued to have
her monthly bevacizumab infusions with her haematologist
as this was not thought to be the cause of her cardiomyopathy
at the time. Three months later, she developed sudden onset
of chest pain and shortness of breath at home and went into
ventricular ﬁbrillation-related cardiac arrest. She underwent
prolonged cardiopulmonary resuscitation but eventually
had return of spontaneous circulation. She was intubated
and admitted to the medical intensive care unit and underwent therapeutic hypothermia. Repeat TTE showed ejection
fraction of 34%. She quietly passed away 3 days later.

3. Discussion
Drug-induced cardiotoxicity usually manifests as heart failure or left ventricular systolic dysfunction. It is commonly
caused by chemotherapeutic medications such as anthracyclines and alkylating agents but is becoming increasingly
reported among biologic drugs such as trastuzumab and
bevacizumab [7].
Bevacizumab is a recombinant humanized monoclonal
IgG1 antibody containing human framework regions and
murine complementarity-determining regions. By binding
to vascular endothelial growth factor (VEGF), bevacizumab
prevents interaction with its receptors (Flt-1 and KDR) on
endothelial cell surfaces therefore inhibiting angiogenesis
[4]. Bevacizumab has shown promising activity and improve
survival of patients with metastatic colon cancer, nonsquamous non-small-cell lung carcinoma, and metastatic breast
cancer. Although not FDA-approved, systemic therapy with
bevacizumab is a recognized treatment for severe forms of
hereditary hemorrhagic telangiectasia (HHT) [5] as was the
case in our patient.
Common side eﬀects include bowel perforations, haemorrhage, delayed wound healing, hypertension, and venous
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and arterial thromboembolism. Left ventricular dysfunction
is a rarely reported side eﬀect of bevacizumab with an incidence of 1.2%, and this occurs irrespective of the route of
administration [6].
In this case, the probability of causal relationship of acute
left ventricular dysfunction and bevacizumab can be rated as
certain based on the World Health Organization and the
Uppsala Monitoring Centre (WHO-UMC) algorithm [8].
As with other antineoplastic medications, the pathogenesis of left ventricular dysfunction is unknown. Several mechanisms have been proposed including the formation of free
radicals in the myocardium and inﬂammatory cytokines with
resultant cardiac depression and congestive heart failure [9].
This side eﬀect appears to be dose dependent, and management involves dose adjustment. Management also involves
guideline-directed medical therapy with ACEi/ARBs, betablockers, and aldosterone antagonists together with diuretics.
Notably patients sick enough to require these medications
also have increased risk of toxicity from these medications.
Other forms of cardiomyopathies such as Takotsubo cardiomyopathy have also been reported following commencement
of bevacizumab [10].
Serial measurement of left ventricular ejection fraction
either by transthoracic echocardiogram or by radionuclide
angiocardiography, as done in patients receiving doxorubicin, may be a useful modality in monitoring patients planned
for bevacizumab therapy via any route while the search for
more sensitive and reliable predictors of eventual left ventricular dysfunction continues.
In conclusion, bevacizumab causes reversible dosedependent left ventricular dysfunction irrespective of the
route of administration. It is prudent for clinicians to consider serial transthoracic echocardiogram and monitoring
of systolic function to facilitate early detection of this medication side eﬀect and dose adjustment. This is particularly
important in patients at high risk of side eﬀects from this
class of drugs such as those with low body mass index,
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advanced age, preexisting or bevacizumab-induced hypertension, and other concurrent chemotherapies [11]. Further
research on the pathogenesis of left ventricular dysfunction
associated with bevacizumab and the creation of a registry
for data synthesis is also needed.
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